Furthermore, more recent large-scale studies describing no involvement of FcγR SNPs in therapeutic responses to anti-cancer mAb therapy have also been published, implying that FCGR3A-F158 may not be as detrimental to PFS as originally thought [316–321]. The gene discussed is FCGR2A; the disease is cancer.